Safety, immunologic and clinical activity of Durvalumab in combination with Olaparib or Cediranib in advanced leiomyosarcoma: Results of the DAPPER clinical trial.

Abdulazeez Salawu Ben X Wang Ming Han Caryn Geady Alya Heirali Hal K Berman Thomas D Pfister Alberto Hernando-Calvo Esmail Mutahar Al-Ezzi Lee-Anne Stayner Abha A Gupta Olubukola Ayodele Bernard Lam Aaron Richard Hansen Anna Spreafico Philippe L Bedard Marcus O Butler Lisa Avery Bryan Coburn Benjamin Haibe-Kains Lillian L Siu Albiruni Abdul Razak

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)

Durvalumab plus olaparib increased immune cell infiltration of TME with clinical benefit in some LMS patients. Baseline M1-macrophage and B-cell activity may identify LMS patients with favorable outcomes on immunotherapy and should be further evaluated.

Keyphrases

clinical trial
end stage renal disease
ejection fraction
chronic kidney disease
newly diagnosed
peritoneal dialysis
prognostic factors
patient reported outcomes
phase ii